These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1319 related articles for article (PubMed ID: 34054126)

  • 1. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
    Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
    Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.
    Ayala-Aguilera CC; Valero T; Lorente-Macías Á; Baillache DJ; Croke S; Unciti-Broceta A
    J Med Chem; 2022 Jan; 65(2):1047-1131. PubMed ID: 34624192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
    Liu WA; Yu L; Morcos PN; Mercier F; Brennan BJ
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1015-1027. PubMed ID: 32424570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
    Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
    Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.
    Wang Y; Nan X; Duan Y; Wang Q; Liang Z; Yin H
    Bioorg Med Chem; 2024 Sep; 111():117870. PubMed ID: 39128361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
    Latham BD; Geffert RM; Jackson KD
    Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic analysis of FDA-approved anticancer drugs.
    Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
    Wu P; Nielsen TE; Clausen MH
    Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug sales confirm clinical advantage of multi-target inhibition of drug escapes by anticancer kinase inhibitors.
    Chen S; Yang SY; Chen Z; Tan Y; Jiang YY; Chen YZ
    Drug Dev Res; 2019 Mar; 80(2):246-252. PubMed ID: 30422335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies.
    Peng Y; Tao H; Gao Y; Yang Y; Chen Z
    Curr Top Med Chem; 2021; 21(5):404-425. PubMed ID: 32543358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
    Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F
    PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuro-ophthalmic side effects of molecularly targeted cancer drugs.
    Bhatti MT; Salama AKS
    Eye (Lond); 2018 Feb; 32(2):287-301. PubMed ID: 29052609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.
    Wu Q; Qian W; Sun X; Jiang S
    J Hematol Oncol; 2022 Oct; 15(1):143. PubMed ID: 36209184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications.
    Tamatam R; Mohammed A
    Eur J Med Chem; 2024 Jun; 272():116441. PubMed ID: 38759455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.